Research programme: antioxidants - Abiogen Pharma

Drug Profile

Research programme: antioxidants - Abiogen Pharma

Alternative Names: Antioxidants - Abiogen Pharma; CNS disorders therapeutics - Abiogen Pharma; CRAM 1-2

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Abiogen Pharma
  • Class
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical CNS disorders

Most Recent Events

  • 19 Jul 2010 Preclinical development is ongoing in Italy
  • 18 Mar 2008 Preclinical trials in CNS disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top